Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Convertible Debt (2022 - 2023)

Historic Convertible Debt for SAB Biotherapeutics (SABSW) over the last 2 years, with Q2 2023 value amounting to $541644.0.

  • SAB Biotherapeutics' Convertible Debt changed N/A to $541644.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $541644.0, marking a year-over-year change of. This contributed to the annual value of $541644.0 for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q2 2023, SAB Biotherapeutics' Convertible Debt is $541644.0.
  • SAB Biotherapeutics' Convertible Debt's 5-year high stood at $541644.0 during Q4 2022, with a 5-year trough of $541644.0 in Q4 2022.